These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33485052)

  • 1. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
    Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
    Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
    Esteban-Rodríguez I; Ruiz Bravo-Burguillos E; Rosas R; Losantos I; Rodríguez-Antolín C; de Castro J
    Rev Esp Patol; 2020; 53(1):10-18. PubMed ID: 31932004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
    Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
    Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H; Lin G; Huang C; Zhu W; Miao Q; Fan X; Wu B; Zheng X; Lin X; Jiang K; Hu D; Li C
    Sci Rep; 2017 Dec; 7(1):16956. PubMed ID: 29209070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
    Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
    Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N; Murakami S; Yokose T; Isaka T; Shinada K; Nagashima T; Adachi H; Shigefuku S; Murakami K; Miura J; Kikunishi N; Watabe K; Saito H; Ito H
    Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    Velcheti V; Patwardhan PD; Liu FX; Chen X; Cao X; Burke T
    PLoS One; 2018; 13(11):e0206370. PubMed ID: 30408065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
    Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.